U
FRTX

UBS’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

UBS’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-7
Closed -$29K – 10855
2013
Q3 		$29K Hold
7
– – ﹤0.01% 7592
2013
Q2 		$71K Buy
+7
New +$77.5K ﹤0.01% 6320

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return

UBS's FRTX Position: Q3 2014 in Review

UBS reduced its Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) stake by 65% in Q3 2014, selling an estimated $42.7K and leaving 6 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #7971.

UBS first reported a position in FRTX in Q2 2013 and has held it in 6 quarters since. The position peaked at $106K in Q4 2013. 60 funds tracked by Wall St. Rank hold FRTX as of Q3 2014.

  • UBS held 6 shares of Fresh Tracks Therapeutics, Inc. Common Stock worth $21K as of Q3 2014.
  • UBS sold 11 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $42.7K.
  • Fresh Tracks Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7971 holding.
  • UBS first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and has held it in 6 quarters since.
  • UBS's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $106K in Q4 2013.
  • 60 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.